Emergent BioSolutions, Inc. (NYSE:EBS)

CAPS Rating: 4 out of 5

A biopharmaceutical company focused on the development, manufacture and commercialization of immunobiotics. The Company operates in two business segments: biodefense and commercial.

Recs

0
Player Avatar NicolasDarvas (< 20) Submitted: 1/6/2011 6:56:16 PM : Outperform Start Price: $23.67 EBS Score: -45.68

Test, 2011.

Featured Broker Partners


Advertisement